FirstSignal

This article from Naturehighlights recent research that provides hope in the fight against COVID-19 variants. The author discusses several potential solutions that have been identified, including the use of monoclonal antibodies, new antiviral drugs, and vaccines that are specifically designed to target new variants.

At First Person Solutions, we're committed to developing and distributing effective treatments globally in the ongoing battle against COVID-19.

COVID’s future: mini-waves rather than seasonal surges Three years after the start of the pandemic, SARS-CoV-2 shows no signs of settling into a seasonal pattern of spread, like influenza has.

We're elated to read that someone is studying long Covid!

U.S. scientists enroll nearly 40,000 patients in high-stakes, $1.2 billion study of long Covid The study, Recover, aims to complete enrollment of 40,000 people and launch clinical trials on potential treatments by the end of the year.

We recently conducted a survey to understand more about the prevalence of Long COVID and more specifically, the symptoms. The survey found that 20% of Respondents Report Suffering from Long COVID-19 Symptoms and that more than half report persistent fatigue. Read more at the link below!

https://bit.ly/3vFC6A6